

Table SI. Primers used to amplify the OTS.

Name	Forward primer (5'-3')	Reverse primer (5'-3')	Size (bp)	sgRNA
OT1	GGACTTGGATCACTATGTCCCT	GCCCTACTGCTCACATTTGG	261	sgRNA1-1
OT2	CACCCCAGGTATTTTCCCCTT	TCCCCTCTTGCCCAGAAAAA	292	sgRNA1-2
OT3	AATCCCTGTTGCTGGTGAGG	CAACGGCATATTCTCCCCCA	183	sgRNA1-2
OT4	TCAAAGGAACTGACTTTCAGACT	TTTTGTGACCCACGTCTTAACAT	209	sgRNA1-2
OT5	CTGTGTATTGCAAGAGTGGCAT	AGGGGAGAGGAGAGCAAATCT	152	sgRNA2-1
OT6	TTAGCAATAGGAGCCACCGC	GCTGGGTTTGGTGGTGAC	210	sgRNA2-1
OT7	AAACAGCAGTCCATATAGCCGT	TTTTCCCCCTTTCGAACACTGAT	131	sgRNA2-1
OT8	GCTTCCCCCACTATAACCAAC	ATGGGTTCTGTCCAGGCTCA	172	sgRNA2-2
OT9	GGCACAGGTTTCTTGGAGGA	GGTTCGGGCCACAAAGAGTA	213	sgRNA2-3
OT10	GGATGTAACATGCACCCAGG	TCAAAGGTCAAATAGTCCCCAAAAG	147	sgRNA2-3
OT11	GAACCGTTTACTCGGGTGGA	GCTTCCCCTCAGGACTCATC	195	sgRNA2-3

OTS, OTS, off-target sites.

Table SII. Clinical parameters of the study subjects.

Parameters	Group	N	<i>BRCAl/2</i> mutation		P-value
			Positive (n=538)	Negative (n=234)	
Age (years)	≤60	431	306	125	0.822
	>60	341	232	109	
Tumor size (cm)	>2	521	408	113	<0.001 ^a
	≤2	251	130	121	
Nodal stage	pN-	261	159	102	0.017 ^a
	pN+	511	379	132	
TNBC status	Not all negative	324	227	107	0.006 ^a
	Negative	438	311	127	
Clinical stage	I-II	224	127	97	0.012 ^a
	III-IV	548	411	137	

Triple-negative breast cancer (TNBC) status indicates the status of ER, PR and HER2. ^aStatistically significant at P<0.05.